Indaptus Therapeutics Stock Performance
| INDP Stock | USD 1.03 0.03 3.00% |
The company retains a Market Volatility (i.e., Beta) of 2.71, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Indaptus Therapeutics will likely underperform. At this point, Indaptus Therapeutics has a negative expected return of -0.41%. Please make sure to check out Indaptus Therapeutics' treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Indaptus Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Indaptus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with uncertain performance in the last few months, the Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Last Split Factor 1:4 | Dividend Date 2020-10-30 | Last Split Date 2021-07-27 |
1 | Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 09/03/2024 |
2 | Indaptus Therapeutics files to sell 1.64M shares of common stock for holders | 09/13/2024 |
3 | Disposition of 2500 shares by Linscott Walt Addison of Indaptus Therapeutics at 72.0 subject to Rule 16b-3 | 09/23/2024 |
4 | Acquisition by Jeffrey Meckler of 12000 shares of Indaptus Therapeutics at 7.0 subject to Rule 16b-3 | 09/26/2024 |
5 | Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit | 10/08/2024 |
6 | Acquisition by Jeffrey Meckler of 75000 shares of Indaptus Therapeutics at 1.105 subject to Rule 16b-3 | 10/09/2024 |
7 | Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data | 10/15/2024 |
8 | Indaptus Therapeutics to Present at Two Upcoming Investor Conferences | 10/23/2024 |
9 | Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer 2024 Annual Mee... | 11/07/2024 |
10 | Acquisition by Michael Newman of 290000 shares of Indaptus Therapeutics at 8.87 subject to Rule 16b-3 | 11/08/2024 |
11 | Acquisition by Maddaluna Anthony J of 12500 shares of Indaptus Therapeutics at 1.82 subject to Rule 16b-3 | 11/11/2024 |
12 | INDP stock touches 52-week low at 1.02 amid market challenges - Investing.com | 11/19/2024 |
13 | Indaptus Therapeutics, Inc. Announces 2. ... | 11/22/2024 |
| Begin Period Cash Flow | 9.6 M |
Indaptus |
Indaptus Therapeutics Relative Risk vs. Return Landscape
If you would invest 158.00 in Indaptus Therapeutics on August 28, 2024 and sell it today you would lose (55.00) from holding Indaptus Therapeutics or give up 34.81% of portfolio value over 90 days. Indaptus Therapeutics is currently does not generate positive expected returns and assumes 7.5676% risk (volatility on return distribution) over the 90 days horizon. In different words, 67% of stocks are less volatile than Indaptus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Indaptus Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Indaptus Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Indaptus Therapeutics, and traders can use it to determine the average amount a Indaptus Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0539
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INDP |
Estimated Market Risk
| 7.57 actual daily | 67 67% of assets are less volatile |
Expected Return
| -0.41 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Indaptus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Indaptus Therapeutics by adding Indaptus Therapeutics to a well-diversified portfolio.
Indaptus Therapeutics Fundamentals Growth
Indaptus Stock prices reflect investors' perceptions of the future prospects and financial health of Indaptus Therapeutics, and Indaptus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Indaptus Stock performance.
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 3.23 M | ||||
| Shares Outstanding | 10.2 M | ||||
| Price To Book | 1.75 X | ||||
| EBITDA | (15.42 M) | ||||
| Net Income | (15.42 M) | ||||
| Cash And Equivalents | 33.01 M | ||||
| Cash Per Share | 4.00 X | ||||
| Total Debt | 175.05 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.18 X | ||||
| Book Value Per Share | 1.44 X | ||||
| Cash Flow From Operations | (13.41 M) | ||||
| Earnings Per Share | (1.70) X | ||||
| Market Capitalization | 10.5 M | ||||
| Total Asset | 14.92 M | ||||
| Retained Earnings | (45.42 M) | ||||
| Working Capital | 11.22 M | ||||
About Indaptus Therapeutics Performance
Assessing Indaptus Therapeutics' fundamental ratios provides investors with valuable insights into Indaptus Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Indaptus Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.03) | (1.09) | |
| Return On Capital Employed | (1.35) | (1.28) | |
| Return On Assets | (1.03) | (1.09) | |
| Return On Equity | (1.28) | (1.21) |
Things to note about Indaptus Therapeutics performance evaluation
Checking the ongoing alerts about Indaptus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Indaptus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Indaptus Therapeutics generated a negative expected return over the last 90 days | |
| Indaptus Therapeutics has high historical volatility and very poor performance | |
| Indaptus Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (15.42 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Indaptus Therapeutics currently holds about 33.01 M in cash with (13.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.0, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Indaptus Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 27.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Indaptus Therapeutics, Inc. Announces 2. ... |
- Analyzing Indaptus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Indaptus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Indaptus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Indaptus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Indaptus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Indaptus Therapeutics' stock. These opinions can provide insight into Indaptus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.